Thyroid follicular cell DNA

The target described as "Thyroid follicular cell DNA via beta radiation from Iodine‑131 uptake" refers not to a conventional molecular target such as a receptor or enzyme but rather the genomic material within the specialized epithelial cells—thyrocytes—of the thyroid gland. These cells uniquely concentrate iodine through the sodium/iodide symporter. When radioactive iodine‑131 is administered, it is selectively taken up by these cells; its beta emissions cause localized ionizing damage primarily to their nuclear DNA. This mechanism underlies both therapeutic ablation for hyperthyroidism and differentiated (papillary or follicular) thyroid cancers that retain iodine-concentrating ability. The actual molecular target for drug action is not a specific protein but rather all cellular components exposed to beta radiation within these iodide-concentrating cells—with nuclear DNA being especially susceptible due to its role in maintaining genetic integrity. The result is irreparable double-strand breaks leading either directly or indirectly via apoptosis pathways to cell death. This entry does not represent a canonical druggable target like an enzyme, transporter, or receptor; instead, it describes an organ-specific cytotoxic effect mediated by radiopharmaceutical localization. Therefore, this should be flagged as "incorrect" per your conventions—it describes a process/mechanism rather than an established molecular entity suitable for structured database targeting[1][4][5].

Other names

Follicular thyroid cell DNAThyrocyte DNAThyroid epithelial cell DNA

Beta radiation from Iodine‑131 causes direct ionization and excitation of molecules within the thyroid follicular cells, leading to double-strand breaks and other forms of DNA damage. This results in cellular death or loss of function, which is exploited therapeutically to ablate hyperfunctioning or malignant thyroid tissue[1][4][5][6][8].